AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03010787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: Open-label single ascending dose
Study NCT06358456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Application of low viscosity artificial tears (Artelac EDO). The active ingredient is hypromellose (1.92 mg per 0.6 ml container).
Study NCT01670552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimesulide + Pantoprazole
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
Study NCT01670552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen + Esomeprazole
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
Study NCT01732757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Description: One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
Study NCT03522909 — intervention group
Intervention type: OTHER
Intervention: Seen in clinic
Description: We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   - Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate
Study NCT00873496 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Study NCT02675699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimisation + HENRY
Description: HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend.
Study NCT02675699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HENRY as standard
Description: Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
Study NCT00190385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic screening
Description: Ultrasonographic screening
Study NCT04123743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trigonella foenum-graceum extract topical cream
Description: Topical cream containing Trigonella foenum-graceum extract
Study NCT04123743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial Wash
Description: Wardah brand facial wash
Study NCT04123743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Wash
Description: Wardah brand facial wash
Study NCT04123743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen Cream
Description: Parasol sunscreen cream SPF 33
Study NCT04123743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Cream
Description: Parasol sunscreen cream SPF 33
Study NCT04123743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical cream
Study NCT00240331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg Rosuvastatin
Study NCT00240331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01624818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac habilitation program
Description: physical activity three weeks
Study NCT02873598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or gemcitabine/abraxane
Description: Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
Study NCT02873598 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
Study NCT03252067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin eyedrop
Description: Tear samples will be collected using the strips.
Study NCT03914456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation treatment
Study NCT04823078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity base therapy
Description: activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching.
Study NCT04823078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strength training
Description: Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
Study NCT01973699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: visualization in shoulder arthroscopy
Description: Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
Study NCT01973699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visualization in shoulder arthroscopy
Description: Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
Study NCT04917588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Saypha® FILLER Lidocaine (HQ)
Description: Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
Study NCT00544635 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: no intervention
Study NCT00544635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light
Description: scars will be treated with light
Study NCT04917588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Saypha® FILLER Lidocaine (C1)
Description: Saypha® FILLER Lidocaine is administered by injection into the lips. The volume applied depends on the size of the area which requires correction and will be selected by the investigator. A maximum volume of 2 mL for both lips in total (i.e., for upper plus lower lip) including touch up might be needed per treatment but the treatment should not exceed 10 mL in total per treatment or 20 mL per year.
Study NCT03025295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is common used to improve the prognosis and life quality of patients.
Study NCT03025295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: It is safe Placebo.
Study NCT02144142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moisturizer with each subject's own antimicrobial bacteria
Study NCT00579605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
Study NCT04648943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ex-Press mini shunt insertion
Study NCT04648943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy
Study NCT05723120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment Respiratory and Neuromuscular
Description: Comparative Score
Study NCT01830621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBI608
Study NCT01830621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01830621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Study NCT01830621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Study NCT00187655 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefotaxime
Description: Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
Study NCT04282551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention with oligosaccharides
Description: intervention with oligosaccharide 1 or 2, or placebo, given once a day
Study NCT04282551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary intervention with oligosaccharides
Description: intervention with oligosaccharide 1 or 2, or placebo, given once a day
Study NCT03383406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy
Description: Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion.
Study NCT00727246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP-Choline
Description: 1000 mg CDP-Choline 2 x per day for 6 weeks.
Study NCT00727246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo for 6 weeks
Study NCT01288820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/piperaquine + primaquine
Description: Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
Study NCT01288820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine + primaquine
Description: Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
Study NCT06358456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No artificial tears
Description: Before artificial tear application, 2 baseline measurements were taken of the cornea without any intervention
Study NCT04652245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3
Description: Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 3
Study NCT04652245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5
Description: Single dose, one spray in each nostril of Placebo nasal spray at Visit 5
Study NCT04652245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5
Description: Single dose, one spray in each nostril of Dymista nasal spray, approximately 137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate per actuation, at Visit 5
Study NCT04652245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3
Description: Single dose, one spray in each nostril of Placebo nasal spray, at Visit 3
Study NCT04115098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study NCT01786707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous stem cells
Description: Pancreatic artery infusion of Autologous Stem cells.
Study NCT01786707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Study NCT01786707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin dose as per clinical management
Study NCT01786707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin dose as per clinical management
Study NCT01786707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dose as tolerated
Study NCT01786707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin dose as tolerated
Study NCT01296581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-82
Description: Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT00542074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hygienic information plus 62% ethyl alcohol in emollient gel
Description: The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
Study NCT00542074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hygienic information
Description: Couples received a brochure with information on control of STI and good hygienic practices.
Study NCT04638465 — intervention group
Intervention type: PROCEDURE
Intervention: Transoral robotic surgery
Description: Transoral resection with neck dissection
Study NCT04638465 — intervention group
Intervention type: DRUG
Intervention: Cisplatin - Dose Level 1
Description: 6 Cycles of 40 mg/m2
Study NCT04638465 — intervention group
Intervention type: DRUG
Intervention: Cisplatin - Dose Level 2
Description: 7 Cycles of 40 mg/m2
Study NCT04638465 — intervention group
Intervention type: RADIATION
Intervention: Dose Level 1
Description: 60 Gy/6 weeks - 2 Gy/fraction, 5 fractions/week
Study NCT04638465 — intervention group
Intervention type: RADIATION
Intervention: Dose Level 2
Description: 70 Gy/7 weeks - 2 Gy/fraction, 5 fractions/week
Study NCT02126540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pantheris Atherectomy System
Description: Treatment device in primary cohort arm; OCT image guided directional atherectomy
Study NCT03424837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCENT
Description: ASCENT includes the following components:~* Survivorship care plan created through the ASCENT tool~* Online tool which assesses health care needs and facilitates receipt of care~* A national-level navigator who helps the participant to access support services~* Periodic reminders for the participant to pursue recommended survivorship care
Study NCT01250717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given by an IV infusion over 1 hour on day 2 of a three-week cycle
Study NCT01250717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
Study NCT02612922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days
Study NCT02612922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study NCT00310817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM conjugate vaccine, adjuvanted
Study NCT00310817 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY polysaccharide vaccine
Study NCT01151085 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Study NCT04274569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaF vanish
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
Study NCT04274569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaF-TCP
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
Study NCT04274569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaF-CPP-ACP
Description: A disposable micro-brush will be used to apply the varnishes to all tooth surfaces. The fluoride varnish will be applied every 3 months, from baseline to 24-months follow-up.
Study NCT04277104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed loop acoustic stimulation
Description: The intervention consists of three consecutive nights of closed loop acoustic stimulation during slow wave sleep. An established closed-loop algorithm is utilized that detects slow oscillations in the electroencephalogram and is programmed to present short tones (50 ms) into their up-states. Tones will be presented via a headband with integrated speakers. The procedure does not wake participants
Study NCT04277104 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acoustic stimulation
Description: Sham acoustic stimulation: participants wear the headband but no stimuli are delivered during slow wave sleep. This ensures that in both the control and the intervention group the conscious experiences are the same.
Study NCT02479594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: competence-feedback
Description: competence-feedback
Study NCT02479594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: control group without competence-feedback
Study NCT02538432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RQ-00000007
Description: RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
Study NCT02538432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RQ-00000007
Description: RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
Study NCT02538432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
Study NCT04085354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multi-Vitamin Tablets
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
Study NCT00659867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes
Description: chromoscopy-guided endomicroscopy with targeted biopsies
Study NCT04085354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.